Research peptide pricing only becomes comparable after normalising to cost per milligram of net peptide, which means correcting the label mass for water, counterion and assayed peptide content. Sequence length, difficult residues and purity specification drive the underlying synthesis cost. Documentation quality is the variable most quotes hide.
- Comparable pricing requires normalising to cost per milligram of net peptide, not per nominal milligram on the vial label.
- HPLC purity is an area percentage among peptide-like species; peptide content is a mass fraction of the dry cake and is the figure that corrects the label.
- Water and counterion together commonly account for 15 to 25 percent of a lyophilized peptide mass.
- Synthesis cost rises superlinearly with sequence length because stepwise coupling yields multiply.
- A purity claim with no chromatogram and no stated method cannot be falsified and should be treated as absent.
- No regulator grades research chemicals, so terms like pharmaceutical grade carry no defined meaning on a research listing.
The vial is the wrong unit
Most price comparisons in this market are run on the wrong denominator. A quote arrives as a figure per vial, the vials are labelled with a nominal mass, and someone divides one by the other and calls it cost per milligram. That number is useful for a purchase order and close to useless for comparing two suppliers, because the label mass is a fill target rather than an assayed quantity of peptide.
The unit that survives scrutiny is cost per milligram of net peptide, delivered, with the documentation you actually need. Every word in that phrase is doing work. Net peptide excludes water and counterion. Delivered folds in freight and any cold-chain surcharge. Documentation you actually need accounts for the fact that a lot with no chromatogram behind it has to be verified in-house or discarded, and both of those cost money.
What follows is the arithmetic, the chemistry that sets the floor on a synthesis price, and the parts of a supplier relationship that show up on the invoice much later than they show up in the paperwork.
- Start with price per vial, not price per mg
- Apply assayed peptide content to get net peptide mass
- Divide price by net mass for effective cost per mg
- Add freight, cold chain and customs to the same line
- Discount any quote whose purity claim has no chromatogram
What drives the underlying synthesis cost
Solid-phase synthesis has a cost structure that is fairly predictable once you know the sequence. Each residue is a coupling step with its own reagent consumption and its own yield, and yields multiply. A 39-residue peptide assembled at 99 percent average stepwise efficiency still loses a third of the material to accumulated truncation and side products before purification begins. That compounding is why length is superlinear in price rather than proportional.
| Driver | Effect on price | Reason |
|---|---|---|
| Sequence length | Superlinear increase | Stepwise yields multiply; longer chains lose more crude mass to truncated species |
| Non-coded residues | Moderate to large increase | Building blocks such as Aib are made in smaller volumes and couple less cleanly |
| Lipidation or PEG conjugation | Large increase | Extra chemistry after assembly, plus a harder purification against closely related species |
| Disulfide bridges | Increase per bridge | Oxidative folding is dilute, slow and gives regioisomers when more than one pair is present |
| Purity specification | Steep near the top | Moving 95 to 99 percent costs chromatography passes and discards material each time |
| Order scale | Decrease per mg | Setup, cleaning validation, analysis and release are fixed costs spread over the lot |
| Counterion exchange | Small increase | Trading trifluoroacetate for acetate is an extra step with its own losses |
| Analytical package | Small to moderate increase | Karl Fischer, amino acid analysis, residual solvent and third-party confirmation are each billable |
A quote well below the plausible cost of goods for a long, lipidated sequence is information. It usually means the material is off-specification, mislabelled as to mass, or something other than what the listing says.
Purity and peptide content are different numbers
This is where most procurement comparisons quietly fail. Chromatographic purity is an area percentage: the main peak divided by the total integrated peak area in an RP-HPLC run at a stated wavelength. It says how much of the peptide-like material is the target. It says nothing about how much peptide is in the vial.
A lyophilized cake also contains water, which for a hygroscopic peptide is routinely 4 to 10 percent by mass, and counterion. Peptides purified by reversed-phase chromatography in trifluoroacetic acid buffers come out as TFA salts, and for a basic sequence with several arginine or lysine residues the trifluoroacetate can account for a substantial fraction of the dry mass. Peptide content, determined by amino acid analysis, nitrogen determination or a validated UV method, is the figure that reconciles the label with reality.
So a vial can honestly carry 99 percent HPLC purity and 78 percent peptide content at the same time. Both numbers are true and they answer different questions. Suppliers who report only the first are not necessarily hiding anything, but a purchaser comparing a content-assayed lot against a purity-only lot is comparing two different quantities and should say so in the file.
Where content is not reported, the honest position is that the delivered mass of peptide is unknown within roughly a fifth. For qualitative screening that may be tolerable. For anything where concentration enters a calculation, it is not.
Worked comparison of three quotes
Same sequence, three suppliers, prices invented for the illustration but proportioned the way real quotes tend to be.
| Quote | Label | Price | Nominal cost/mg | HPLC purity | Peptide content | Effective cost/mg |
|---|---|---|---|---|---|---|
| A | 10 mg | $46.00 | $4.60 | 98.5%, chromatogram supplied | 82% by AAA | $5.61 |
| B | 5 mg | $30.00 | $6.00 | 99.1%, chromatogram supplied | 91%, acetate salt | $6.59 |
| C | 10 mg | $34.00 | $3.40 | “99%”, no method, no trace | Not reported | Indeterminate |
The arithmetic for A: 10 mg × 0.82 = 8.2 mg net peptide, then $46.00 ÷ 8.2 mg = $5.61/mg. For B: 5 mg × 0.91 = 4.55 mg, then $30.00 ÷ 4.55 mg = $6.59/mg. Quote C cannot be normalised at all, and the cheapest nominal figure on the page is the one that carries no defensible number.
Ranking flips once content is applied often enough that the exercise is worth doing every time. The cost per mg tool runs the comparison across vial sizes, and the vial concentration calculator converts a corrected mass into the concentration a protocol will actually see.
Documentation that should arrive with the lot
A certificate of analysis is a claim about one specific lot, tested on a stated date by a named party. Anything that describes a product line rather than a lot is marketing with a laboratory typeface.
- Lot or batch identifier that matches the vial label exactly, plus manufacture and analysis dates.
- Identity by mass spectrometry, reported as observed mass against theoretical, with the mass type stated. Monoisotopic and average masses differ by several units on a peptide this size, and a certificate that does not say which it used has not told you whether the numbers agree.
- An RP-HPLC purity result with the method attached: column chemistry and dimensions, gradient, flow, detection wavelength, and the integrated trace itself with legible axes.
- Water content by Karl Fischer or loss on drying.
- Counterion identity and, ideally, content.
- Peptide content, with the method named.
- Appearance and solubility as observed, not as expected.
- Signature or initials of the analyst, and the testing party if analysis was contracted out.
Two absences deserve particular attention. A purity figure with no chromatogram is unfalsifiable. And a certificate whose analysis date precedes the manufacture date, which happens more than it should, indicates the document was assembled from a template. Our own quality standard sets out which of these items accompany each lot as issued.
Sterility and endotoxin testing are usually absent from research-grade documentation, and their absence is not a defect. Research material is not manufactured under the sterility controls of a licensed medicine, and a certificate implying otherwise is overreaching.
Evaluating a supplier without taking their word for it
Ask for the certificate for a specific lot before ordering, not the generic example. Then read the trace. If the same chromatogram appears under several lot numbers, or the peak retention time drifts while the reported purity stays fixed at a suspiciously round figure, the documents are being reused.
Cross-check the identity claim against a public record. PubChem carries molecular formula, exact mass and CAS registry entries for well-characterised compounds, and a supplier listing whose formula or mass disagrees with the public record has either a typographical error or a different molecule. That check takes two minutes and catches a meaningful fraction of mislabelled listings.
Other things to weigh: whether the supplier will name the analytical laboratory; whether they will send a lot for independent confirmation without argument; whether they answer a technical question with a technical answer; and how the listing is written. Therapeutic or outcome language on a research listing tells you which customer the seller is really writing for, and that customer's expectations shape what the documentation is for.
Reorder consistency is the slowest and most informative test. Lot-to-lot variation in purity and content is normal; unexplained drift in the specification itself, or a certificate that suddenly loses a section it used to carry, is a change in the supply chain that nobody announced.
Costs that never appear on the quote
Freight and cold chain are the obvious ones. Dry powder tolerates ambient transit far better than solution does, so insulated shipping without active cooling is often adequate and the surcharge for gel packs buys less than it appears to. Conditions and lead times for our own dispatch are set out under shipping. Customs handling and any brokerage fee land on the same line and are frequently forgotten in a per-milligram comparison.
Then the internal costs. Verifying an undocumented lot in-house consumes instrument time and a portion of the material. Minimum order quantities create material that expires before it is used, and a discount on quantity you cannot consume is not a discount. A failed lot costs the purchase price plus the experiments run against it before anyone noticed, which is usually the largest number in this whole discussion.
Handling losses belong here too. Every avoidable freeze-thaw cycle and every vial opened cold enough to condense water inside it converts purchased material into waste, which is the practical link between storage discipline and unit cost. The storage and stability guide covers the mechanisms, and diluent choice is treated in the bacteriostatic water guide.
Regulatory position
No regulator issues a grade or a quality ranking for research chemicals. Terms such as pharmaceutical grade, when applied to material supplied for laboratory use, have no defined meaning and no issuing authority behind them. A certificate of analysis is a supplier claim about a lot, testable and falsifiable, and that is the extent of it.
Where a compound also exists as an approved medicine, that medicine is manufactured under pharmaceutical quality systems covering sterility, endotoxin, formulation and lot release, and is available only on prescription. Research material sits outside that framework entirely and has never been a lawful route to human use. Import of research chemicals is subject to national customs and controlled-substance rules that vary by jurisdiction and are the purchaser’s responsibility to confirm.
Status verified 26 August 2026.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Common questions
Why do two suppliers quote such different prices for the same sequence?
Is peptide content the same thing as HPLC purity?
How much does the counterion matter to the delivered mass?
What is the single most useful thing to ask for before ordering?
Are bulk discounts worth taking?
Does third-party testing justify a higher price?
More procurement guides
Sources
- United States Pharmacopeia, General Chapter <621> Chromatography. Defines system suitability, resolution and integration expectations that any credible RP-HPLC purity figure depends on; supports the position that a purity claim without a stated method is uninterpretable.
- ICH Q6B, Specifications for Biotechnological and Biological Products. Establishes the principle that a specification is a lot-release claim tied to defined analytical procedures and acceptance criteria; supports the certificate-of-analysis content list.
- PubChem, NIH National Library of Medicine. Public compound records giving molecular formula, exact mass and CAS registry numbers; used as the independent cross-check against a supplier identity claim.
- Peer-reviewed reviews of solid-phase peptide synthesis process economics. Established generally in the synthesis literature that stepwise coupling yields multiply and that non-coded residues, lipidation and disulfide folding each add cost; supports the price-driver table.
